Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Readiness to Consider and Adopt Genetic and Genomic Tests in Canada-An Update to the State of Readiness Report.

Current oncology (Toronto, Ont.)·2026
Same author

Structured Exercise Program After Adjuvant Chemotherapy for Colon Cancer: A Cost-Utility Analysis of the CHALLENGE Trial.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025.

Current oncology (Toronto, Ont.)·2026
Same author

Clinical and molecular correlates of circulating tumor fraction in patients with metastatic pancreatic ductal adenocarcinoma.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026
Same author

Life Years Gained and Healthcare Dollars Saved: National Economic Evidence Supporting Comprehensive Genomic Profiling as Standard of Care for Canadian Cancer Patients.

Current oncology (Toronto, Ont.)·2026
Same author

Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Settings (2025 Update).

Current oncology (Toronto, Ont.)·2026

Related Experiment Video

Updated: May 7, 2026

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

15.8K

Toward Timely and Equitable Advanced Biomarker Testing for Patients with Metastatic Cancer in Canada.

Brandon S Sheffield1, Shantanu Banerji2, Allen Chankowsky3

  • 1William Osler Health System, Brampton, ON L6R 3J7, Canada.

Current Oncology (Toronto, Ont.)
|March 26, 2025
PubMed
Summary

Equitable access to advanced biomarker testing in Canada is crucial for precision cancer care. Key themes include adopting comprehensive genomic profiling and utilizing liquid biopsies for advanced cancer patients.

Keywords:
biomarker testingcirculating tumor DNA (ctDNA)comprehensive genomic profilinggenomic medicinegenomic testingliquid biopsymolecular testingmutational testingnext generation sequencingprecision medicine

More Related Videos

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.0K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

Related Experiment Videos

Last Updated: May 7, 2026

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications
14:14

Adaptation of Semiautomated Circulating Tumor Cell CTC Assays for Clinical and Preclinical Research Applications

Published on: February 28, 2014

15.8K
Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay
07:44

Practical Considerations in Studying Metastatic Lung Colonization in Osteosarcoma Using the Pulmonary Metastasis Assay

Published on: March 12, 2018

10.0K
Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer
08:12

Detection of a Circulating MicroRNA Custom Panel in Patients with Metastatic Colorectal Cancer

Published on: March 14, 2019

5.4K

Area of Science:

  • Oncology
  • Genetics
  • Health Policy

Background:

  • Biomarker testing has revolutionized cancer care by enabling precision medicine, improving survival, and enhancing quality of life, particularly for advanced/metastatic disease.
  • Research into the genetic basis of cancer benefits from extensive databases of mutations, therapies, and outcomes.
  • Despite advancements, equitable access to biomarker testing remains a significant challenge across Canada.

Purpose of the Study:

  • To address the inequities in advanced biomarker testing access for Canadian metastatic cancer patients.
  • To identify strategies for improving the adoption and accessibility of precision oncology tools.
  • To foster collaboration among stakeholders to advance equitable cancer care.

Main Methods:

  • A Canadian conference convened patients, clinicians, researchers, policy-makers, and scientists in 2024.
  • Discussions focused on "Equitable Access to Advanced Biomarker Testing for Canadian Metastatic Cancer Patients."
  • Key themes were identified through collaborative dialogue and consensus-building.

Main Results:

  • Two major themes emerged: the urgent need to implement comprehensive genomic profiling (CGP) as a standard of care in Canada.
  • The emerging role of liquid biopsy was highlighted as a method to accelerate biomarker testing access for patients with advanced/metastatic cancer.
  • Identified barriers include the need for infrastructure investment, process standardization, and robust cost/benefit evaluation methods.

Conclusions:

  • Comprehensive genomic profiling (CGP) should be adopted as standard care across Canada to ensure equitable access.
  • Liquid biopsy presents a promising avenue for improving timely access to essential biomarker information for metastatic cancer patients.
  • Addressing systemic issues in laboratory medicine and funding is critical for achieving equitable biomarker testing nationwide.